January 2009 - Page 9 of 19

FridayJan 16, 2009 1:12 pm

HST Global, Inc. (HSTC.OB) Operates in a Recession Proof Industry

Due to the dreadful nature of cancer, HST Global, Inc. is not as affected by turbulent economic conditions. The Company’s intent is to provide World-Class treatment of cancer, as well as other life threatening diseases, regardless of the world’s economy. During the past month, HSTC.OB has been trading around $2.00. According to Small Cap Insider’s Report, the trading action is very reminiscent of a company called Health South (HLS). HLS spent most of its life on the pink sheet market in the same range, and now trades on the NYSE near $11.00. Let us hear your thoughts: HST Global, Inc.…

FridayJan 16, 2009 12:55 pm

HST Global, Inc. (HSTC.OB) has Established a Strategic Plan for Profitable Growth

The growing acceptance and demand for alternative cancer treatments around the world has perfectly positioned HST Global to launch its own brand of Cancer Treatment Centers. While the company continues to look for in-licensing pre-clinical drug candidates, this strategy will enable company to address the challenges individuals face in the treatment of cancer in the later stages. There is a growing population of individuals that are suffering as a result of the lack of available alternatives in treating late stage cancer. HST Global, Inc. has been working with a number of highly visible physicians that are developing and have developed…

FridayJan 16, 2009 12:41 pm

Keep HST Global, Inc. (HSTC.OB) on Your Radar!

HST Global, Inc. is a development-stage biotechnology company committed to acquiring, developing and commercializing innovative products to enhance cancer care. The company determines to acquire proprietary rights to these products, fund their R&D, and bring the products to market. Since HST’s inception, they have focused their efforts and resources primarily on Salicinium, a clinical stage drug candidate, as well as raising capital and recruiting personnel. The company’s focus is on in-licensing and further advancing drug candidates that are undergoing or have already completed initial clinical testing for the treatment of cancer. Although the cost of licensing drug candidates that have…

FridayJan 16, 2009 7:09 am

Stereotaxis, Inc. (STXS) Reports Preliminary Fourth Quarter Results

Today, Stereotaxis announced that it expects revenue for its fourth quarter ended December 31, 2008 to total approximately $12 million, which is 17% greater than the revenues generated during the same quarter in 2007. Furthermore, the company stated it anticipates a net backlog of Niobe and Odyssey systems of approximately $70 million. "Our preliminary fourth quarter revenue results demonstrate that even in the current environment of constrained hospital capital equipment spending, Stereotaxis systems continue to be regarded as strategically important to the installation of electrophysiology (EP) cath labs ," said Michael P. Kaminski, Stereotaxis President and CEO. "We also are…

FridayJan 16, 2009 6:55 am

ERF Wireless, Inc. (ERFW.OB) and Schlumberger (SLB) Enter Exclusive Reseller Agreement for United States and Canada

Today before the bell, ERF Wireless, Inc. and Schlumberger announced that they have signed an exclusive agreement for delivery of wireless broadband services throughout North America. As terms of the agreement, Schlumberger will exclusively resell wireless broadband and WiMAX terrestrial communications products and services from ERF Wireless in the North American oil and gas market. "This joint contract with ERF Wireless provides Schlumberger with the ability to deliver cost effective ubiquitous communications to the oil and gas industry in the ERF Wireless coverage areas," stated Slavo Pastor, vice president, Schlumberger Information Solutions, North America. "This will increase real-time activities and…

FridayJan 16, 2009 6:50 am

RTI Biologics, Inc. (RTIX) Announces Unaudited Revenues for 2008; Projects 2009 Revenues

RTI Biologics, a company focused on providing sterile biological implants for surgeries around the world, announced that its unaudited 2008 full year revenues are $146.6 million and fourth quarter revenues are $37.3 million, both up significantly from 2007’s full year revenues of $94.2 million and fourth quarter revenues of $25.5 million. The increase in year-over-year revenues was primarily caused by the inclusion Tutogen Medical’s revenues since the completion of the merger last February. The company also also reiterated today that its outlook for 2009 full year revenues is anticipated to be between $166 million and $168 million with earnings per…

FridayJan 16, 2009 6:05 am

Placing a Value on Kraig Biocraft Laboratories, Inc. (KBLB.OB) Technology

Emerging Growth Research, LLP recently completed a 25 page research report on Kraig Biocraft Laboratories, Inc. and its Spider Silk technology. To establish a value for the “super fiber,” the research bureau evaluated the success of DuPont’s Kevlar, which currently brings in more than $5 billion a year from sales of Kevlar. After the evaluation, Emerging Growth Research concluded that Kevlar is worth approximately $8 billion. If Kraig Biocraft makes a substantial breakthrough in the laboratory and is able to further refine its technology to produce commercial amounts, the technology will be immediately worth potentially several hundred million dollars to…

FridayJan 16, 2009 5:45 am

Stay on the Look Out for Axial Vector Energy Corp. (AXVC.PK) Acquisitions

In September of last year, Axial Vector Energy Corp. announced that it had formed a wholly-owned subsidiary solely focused on acquisition. The new subsidiary, AVEC Strategic Acquisitions Corp., is led by Mr. Sanjai Chhaunker, the President and CEO of Axial Vector. Mr. Sanjai is working alongside Mr. Behzad Khakouei, Director of Strategic planning at AVEC. Mr. Chhaunker, stated, “Our strategic plan calls for acquiring businesses that complement our core technology and allow our revenue stream to grow more rapidly. With the proper structure and financing now in place, we will proceed to finalize our discussions on companies that we have…

FridayJan 16, 2009 5:26 am

Hunt Gold Corp. (HGLC.PK) Enters Agreement to Sell “Lookout Silver Mine”

Today, Hunt Gold announced that it is disposing of its “Lookout Silver" Mine. According to the press release, the company is in the process of staking additional claims surrounding the mine and is selling the entire package. The decision to sell the assets was made to allow Hunt Gold to maintain an exclusive focus on its Gold Mining interests and obtain additional funds to finance the massive expedited exploration and drilling campaigns currently underway. The $65 million in proceeds from the sale of the "Lookout Silver" Mine package are being retained by the Company. Hunt Gold anticipates the conclusion of…

ThursdayJan 15, 2009 6:04 pm

Sector 10, Inc. (SECT.OB) and Kraig Biocraft Laboratories, Inc. (KBLB.OB) Close Thursday’s Trading Session with Large Gains

Sector 10, Inc. (SECT.OB) continued to trend towards higher prices today, closing at its high of day at $0.09, up 28.57% from yesterday's close. Since we featured the company in early December, the stock has risen 450%! Kraig Biocraft Laboratories, Inc. (KBLB.OB) also did extremely well, posting 185.71% gains by the end of the trading day. Over 71,000 shares were traded today, substantially higher than the 3-month average daily volume of 3,175. Continue to watch these two companies as continue to outperform the market and aim for even greater heights!

Site Search

Company Search

Month: January 2009